Gastric cancer Trials in Milan, Italy
Conditions / Gastric cancer / Milan, Italy
Gastric cancer has been the subject of sustained clinical investigation across multiple research sites.
52 total trials for this combination
Showing top 10 of 52 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04498767 | Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) | RECRUITING | NA |
| NCT07431281 | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | RECRUITING | PHASE3 |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | TERMINATED | PHASE1/PHASE2 |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | RECRUITING | PHASE2 |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | COMPLETED | PHASE1/PHASE2 |
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | COMPLETED | PHASE1 |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT01702558 | A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC) | TERMINATED | PHASE2 |
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT05489211 | Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | RECRUITING | PHASE2 |